People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial
2013-03-18 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 18 March 2013 - Novo Nordisk today announced the headline results from a 56-week, double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in overweight or obese people with type 2 diabetes. This is the second phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment. Further information Media: Katrine Sperling +45 3079 6718 [email protected] Ken Inchausti +1 609 786 8316 [email protected] Ambre Morley +1 609 987 5898 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 19 / 2013
The release as fetched from its publisher. novonordisk.com ↗